Bactolife

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

BactolifeTM was established in 2017 by a group of senior executives from the biotech industry together with top scientific talents, with the aim of adding a new approach to improving gastrointestinal health for animals and humans in a manner that is safe, cost efficient, and does not create antimicrobial resistance (AMR). BactolifeTM has developed a pipeline of projects within animal and human health based on its VIPTM technology where specially designed proteins protect the microbiome by inactivation of pathogenic virulence factors leaving the healthy microbiome intact.

Bactolife

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

BactolifeTM was established in 2017 by a group of senior executives from the biotech industry together with top scientific talents, with the aim of adding a new approach to improving gastrointestinal health for animals and humans in a manner that is safe, cost efficient, and does not create antimicrobial resistance (AMR). BactolifeTM has developed a pipeline of projects within animal and human health based on its VIPTM technology where specially designed proteins protect the microbiome by inactivation of pathogenic virulence factors leaving the healthy microbiome intact.

Bactolife

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

BactolifeTM was established in 2017 by a group of senior executives from the biotech industry together with top scientific talents, with the aim of adding a new approach to improving gastrointestinal health for animals and humans in a manner that is safe, cost efficient, and does not create antimicrobial resistance (AMR). BactolifeTM has developed a pipeline of projects within animal and human health based on its VIPTM technology where specially designed proteins protect the microbiome by inactivation of pathogenic virulence factors leaving the healthy microbiome intact.